BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21054566)

  • 1. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response.
    Fantini F; Greco A; Del Giovane C; Cesinaro AM; Venturini M; Zane C; Surrenti T; Peris K; Calzavara-Pinton PG
    J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):896-901. PubMed ID: 21054566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial.
    Surrenti T; De Angelis L; Di Cesare A; Fargnoli MC; Peris K
    Eur J Dermatol; 2007; 17(5):412-5. PubMed ID: 17673385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma.
    Szeimies RM
    Dermatol Clin; 2007 Jan; 25(1):89-94. PubMed ID: 17126746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies.
    Foley P; Freeman M; Menter A; Siller G; El-Azhary RA; Gebauer K; Lowe NJ; Jarratt MT; Murrell DF; Rich P; Pariser DM; Oseroff AR; Barnetson R; Anderson C; Kossard S; Gibson LE; Tope WD
    Int J Dermatol; 2009 Nov; 48(11):1236-45. PubMed ID: 20064185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reflectance confocal microscopy allows in vivo real-time noninvasive assessment of the outcome of methyl aminolaevulinate photodynamic therapy of basal cell carcinoma.
    Venturini M; Sala R; Gonzàlez S; Calzavara-Pinton PG
    Br J Dermatol; 2013 Jan; 168(1):99-105. PubMed ID: 23013443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma.
    Annemans L; Caekelbergh K; Roelandts R; Boonen H; Leys C; Nikkels AF; van Den Haute V; van Quickenborne L; Verhaeghe E; Leroy B
    Eur J Dermatol; 2008; 18(5):539-46. PubMed ID: 18693157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment.
    Horn M; Wolf P; Wulf HC; Warloe T; Fritsch C; Rhodes LE; Kaufmann R; De Rie M; Legat FJ; Stender IM; Solér AM; Wennberg AM; Wong GA; Larkö O
    Br J Dermatol; 2003 Dec; 149(6):1242-9. PubMed ID: 14674903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience and BCC subtypes as determinants of MAL-PDT response: preliminary results of a national Brazilian project.
    Ramirez DP; Kurachi C; Inada NM; Moriyama LT; Salvio AG; Vollet Filho JD; Pires L; Buzzá HH; de Andrade CT; Greco C; Bagnato VS
    Photodiagnosis Photodyn Ther; 2014 Mar; 11(1):22-6. PubMed ID: 24412582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
    Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
    J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma.
    Vinciullo C; Elliott T; Francis D; Gebauer K; Spelman L; Nguyen R; Weightman W; Sheridan A; Reid C; Czarnecki D; Murrell D
    Br J Dermatol; 2005 Apr; 152(4):765-72. PubMed ID: 15840111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy.
    Gracia-Cazaña T; Mascaraque M; Lucena SR; Vera-Álvarez J; González S; Juarranz Á; Gilaberte Y
    PLoS One; 2019; 14(4):e0215537. PubMed ID: 31017970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma.
    Kuijpers DI; Thissen MR; Thissen CA; Neumann MH
    J Drugs Dermatol; 2006; 5(7):642-5. PubMed ID: 16865869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giant and large basal cell carcinoma treated with topical photodynamic therapy.
    Eibenschutz L; Marenda S; Buccini P; De Simone P; Ferrari A; Mariani G; Silipo V; Catricalà C
    Eur J Dermatol; 2008; 18(6):663-6. PubMed ID: 18955200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined carbon dioxide laser with photodynamic therapy for nodular and superficial basal cell carcinoma.
    Shokrollahi K; Javed M; Aeuyung K; Ghattaura A; Whitaker IS; O'Leary B; James W; Murison M
    Ann Plast Surg; 2014 Nov; 73(5):552-8. PubMed ID: 23407256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up.
    Szeimies RM; Ibbotson S; Murrell DF; Rubel D; Frambach Y; de Berker D; Dummer R; Kerrouche N; Villemagne H;
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1302-11. PubMed ID: 18624836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
    Roozeboom MH; Aardoom MA; Nelemans PJ; Thissen MR; Kelleners-Smeets NW; Kuijpers DI; Mosterd K
    J Am Acad Dermatol; 2013 Aug; 69(2):280-7. PubMed ID: 23566914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
    Campbell SM; Morton CA; Alyahya R; Horton S; Pye A; Curnow A
    Br J Dermatol; 2008 Aug; 159(2):387-93. PubMed ID: 18544077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy in the management of basal cell carcinoma: Retrospective evaluation of outcome.
    Jerjes W; Hamdoon Z; Hopper C
    Photodiagnosis Photodyn Ther; 2017 Sep; 19():22-27. PubMed ID: 28442314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes.
    Caekelbergh K; Nikkels AF; Leroy B; Verhaeghe E; Lamotte M; Vincent R
    J Drugs Dermatol; 2009 Nov; 8(11):992-6. PubMed ID: 19894366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.